Shots: Vifor and Janssen collaborated to jointly commercialize Invokana (canagliflozin) to treat DKD and to reduce the risk of hospitalization for heart failure in patients with T2D and DKD in […]readmore
Tags : INVOKANA
Shots: The approval is based on P-III CREDENCE study evaluating the renal outcomes of Invokana + SoC vs PBO in 4,401 patients with T2D with stage II/III DKD and macroalbuminuria […]readmore
Shots: The P-III CREDENCE study results involves assessing of Invokana (100 mg, qd) vs PBO in patients 4,401 patients in ratio (1:1) with T2D and stage II &III CKD prior […]readmore
Shots: The approval is based on the results of CANVAS (CANagliflozin cardioVascular Assessment Study) Program assessing Invokana vs PBO + SoC in 10,000 adults having or at risk CV disease […]readmore
Shots: Mundipharma has gained exclusive distribution rights from Janssen for Europe and Switzerland excluding Spain The drug is recommended for Type 2 Diabetes Mellitus (T2DB) patients with adverse CV disease […]readmore